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inhibitors (HMGs). OBJECTIVE: The primary objective
is to determine if there are differences among specific
HMGs regarding the incidence of rhabdomyolysis. The
secondary objective is to identify significant risk factors
associated with rhabdomyolysis such as age, gender, and
concurrent gemfibrozil use. METHODS: Retrospective
pharmacy and medical claims from a large managed care
organization were analyzed. Patients were included if
they received any HMG (cerivastatin, fluvastatin, ator-
vastatin, lovastatin, pravastatin, or simvastatin) during
the period between 7/1/99 to 12/31/99. All patients were
followed for 6 months. ICD-9 diagnosis codes for rhab-
domyolysis (idiopathic), myalgia and myositis not other-
wise specified, or adverse effect to antilipemics were used
to define rhabdomyolysis events. RESULTS: There were
133,454 patients identified who received an HMG during
the identification period. The average age was 67.8 years
(S.D.  11.1) and 51.5% were female. The rates of rhab-
domyolysis with and without concurrent gemfibrozil use
were 0.861% and 0.632%, respectively (P  0.13).
Overall, the incidence across individual drugs was similar
for cerivastatin [0.486%(95%CI  0.363%–0.609%)],
fluvastatin [0.679%(95%CI  0.589%–0.769%)], ator-
vastatin [0.889%(95%CI  0.783%–0.995%)], lovasta-
tin [0.741%(95%CI  0.158%–1.332%)], pravastatin
[0.530%(95%CI  0.468%–0.592%)], and simvastatin
[0.378%(95%CI  0.212%–0.544%)]. With concurrent
gemfibrozil use, the incidence was significantly higher for
cerivastatin [6.341%(95%CI  3.005%–9.677%)] com-
pared to fluvastatin [0.713%(95%CI  0.000%–1.439%)],
atorvastatin [0.494%(95%CI  0.062%–0.926%)], lo-
vastatin (0.0%), pravastatin [0.452%(95%CI  0.091%–
0.813%)], and simvastatin (0.0%). In a logistic regres-
sion model, there was no significant relationship between
the incidence of rhabdomyolysis and age or gender.
CONCLUSION: In this population, it appears that the
risk of rhabdomyolysis is substantially higher when ceriv-
astatin is used concurrently with gemfibrozil. The find-
ings of this analysis indicate there is a substantial need
for managed care organizations and pharmacy benefits
management companies to proactively prevent the con-
current use of cerivastatin and gemfibrozil.
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OBJECTIVES: Trials of anticoagulation in non-rheu-
matic atrial fibrillation have demonstrated a reduction in
the risk of stroke by two-thirds. In these trials, the safety
of anticoagulation appeared good, but this may be re-
lated to highly selected patient groups. Exclusion rates of
93% were reported. Participants may have had fewer
complications than might be expected among less se-
lected patients in clinical practice. No trials had actually
looked at the costs of anticoagulation in a real day-to-day
clinical practice. The aim of this study is to investigate
the actual cost of warfarin treatment of atrial fibrillation
in a real clinical practice. METHODS: A one-year retro-
spective study involving patients of all ages admitted to
hospital with non-rheumatic atrial fibrillation on long-
term oral anticoagulation. Patients were interviewed and
their medical records reviewed. The costs of anticoagula-
tion were viewed as follows: 1. The cost of the active
drug. 2. The cost of monitoring the patient’s INR i.e.
traveling costs, staffing cost, and analysis costs. 3. The
costs associated with bleeding complications. RESULTS:
We studied 139 patients. The mean (SD) age was 73.6
(8.9) years, ranging from 41 to 93 years. The mean dura-
tion of oral anticoagulant therapy was 36 months (range
2 to 105 months), forming a total of 417 patient-years of
treatment. Mean (SD) INR was 2.5 (0.36). The target
range of 2.0–3.0 was achieved 54% of the time. Bleeding
occurred in 21 patients, with incidence of 7.2% per pa-
tient-year for minor bleeding, 2.4% per patient-year for
major bleeding and 0.2% for fatal bleeding. The cost of
warfarin tablets was £14.6 ($23.36), per patient-year,
but was £262.6 ($420.16), per patient-year after consid-
ering monitoring and bleeding complication costs. The
cost per stroke prevented was estimated at £8,141
($13,026). CONCLUSION: Anticoagulation appeared
safe and cost-effective in clinical practice but control was
not as good as in clinical trials.
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OBJECTIVES: To evaluate the quality of care given to
older patients hospitalised with heart failure and to iden-
tify areas in which treatment could be improved. METH-
ODS: A two-year retrospective study involving the analy-
sis of the case notes of a random sample of 145 elderly
patients (aged 
75 yrs) admitted to hospital with heart
failure. From The International Classification of Dis-
eases, we identified patients with a principle discharge di-
agnosis of heart failure (ICD codes 428.0-428.1-428.9).
Cases were excluded if the diagnosis could not be vali-
dated by medical record review. A total of one hundred
and forty five patients formed all the admissions with
heart failure during the study period. The standard of
care received was evaluated using the relevant quality of
care indicators derived from the Agency for Health Care
Policy and Research (AHCPR) Clinical Practice Guide-
lines. RESULTS: The study sample included 145 patients.
The mean age (SD) was 82 (5) years. Symptoms and signs
of heart failure were documented in 145 (100%) pa-
tients. All patients with symptoms and signs of hypervol-
aemia received diuretic therapy. Only fifty-five patients
(38%) had an objective assessment of left ventricular
